- Home
- OCS vs ZYME Comparison
OCS vs ZYME Comparison
Compare OCS & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCS
- ZYME
- Stock Information
- Founded
- OCS 2003
- ZYME 2003
- Country
- OCS Switzerland
- ZYME United States
- Employees
- OCS N/A
- ZYME N/A
- Industry
- OCS Biotechnology: Pharmaceutical Preparations
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- OCS Health Care
- ZYME Health Care
- Exchange
- OCS Nasdaq
- ZYME Nasdaq
- Market Cap
- OCS 956.4M
- ZYME 968.5M
- IPO Year
- OCS N/A
- ZYME 2017
- Fundamental
- Price
- OCS $17.09
- ZYME $16.14
- Analyst Decision
- OCS Strong Buy
- ZYME Buy
- Analyst Count
- OCS 4
- ZYME 7
- Target Price
- OCS $35.75
- ZYME $20.00
- AVG Volume (30 Days)
- OCS 13.4K
- ZYME 446.7K
- Earning Date
- OCS 11-06-2025
- ZYME 10-30-2025
- Dividend Yield
- OCS N/A
- ZYME N/A
- EPS Growth
- OCS N/A
- ZYME N/A
- EPS
- OCS N/A
- ZYME N/A
- Revenue
- OCS $960,668.00
- ZYME $122,867,000.00
- Revenue This Year
- OCS $11.49
- ZYME $107.76
- Revenue Next Year
- OCS $1,784.02
- ZYME $2.35
- P/E Ratio
- OCS N/A
- ZYME N/A
- Revenue Growth
- OCS N/A
- ZYME 95.94
- 52 Week Low
- OCS $11.78
- ZYME $9.03
- 52 Week High
- OCS $23.08
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- OCS 44.25
- ZYME 67.72
- Support Level
- OCS $16.00
- ZYME $14.88
- Resistance Level
- OCS $17.35
- ZYME $15.52
- Average True Range (ATR)
- OCS 0.39
- ZYME 0.65
- MACD
- OCS 0.06
- ZYME 0.12
- Stochastic Oscillator
- OCS 51.67
- ZYME 88.45
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.